VLCAD deficiency

Follow-up and outcome of patients diagnosed through newborn screening in Victoria

Maureen Evans, Brage S. Andresen, Judy Nation, Avihu Boneh

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inherited metabolic disorder of fatty acid oxidation. Treatment practices of the disorder have changed over the past 10–15 years since this disorder was included in newborn screening programs and patients were diagnosed pre-symptomatically. A genotype-phenotype correlation has been suggested but the discovery of novel mutations make this knowledge limited. Herein, we describe our experience in treating patients (n = 22) diagnosed through newborn screening and mutational confirmation and followed up over a median period of 104 months. We report five novel mutations. In 2013 we formalised our treatment protocol, which essentially follows a European consensus paper from 2009 and our own experience. The prescribed low natural fat diet is relaxed for patients who are asymptomatic when reaching age 5 years but medium-chain triglyceride oil is recommended before and after physical activity regardless of age. Metabolic stability, growth, development and cardiac function are satisfactory in all patients. There were no episodes of encephalopathy or hypoglycaemia but three patients had episodes of muscle pain with our without rhabdomyolysis. Body composition studies showed a negative association between dietary protein intake and percent body fat. Larger patient cohort and longer follow up time are required for further elucidation of genotype-phenotype correlations and for establishing the role of dietary protein in metabolic stability and long-term healthier body composition in patients with VLCAD deficiency.

Original languageEnglish
Pages (from-to)282-287
Number of pages6
JournalMolecular Genetics and Metabolism
Volume118
Issue number4
DOIs
Publication statusPublished - 1 Aug 2016
Externally publishedYes

Keywords

  • Body composition
  • Fatty acid oxidation
  • VLCAD deficiency

Cite this

@article{464b6d4b437f48aca5724eba5c2c2fa5,
title = "VLCAD deficiency: Follow-up and outcome of patients diagnosed through newborn screening in Victoria",
abstract = "Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inherited metabolic disorder of fatty acid oxidation. Treatment practices of the disorder have changed over the past 10–15 years since this disorder was included in newborn screening programs and patients were diagnosed pre-symptomatically. A genotype-phenotype correlation has been suggested but the discovery of novel mutations make this knowledge limited. Herein, we describe our experience in treating patients (n = 22) diagnosed through newborn screening and mutational confirmation and followed up over a median period of 104 months. We report five novel mutations. In 2013 we formalised our treatment protocol, which essentially follows a European consensus paper from 2009 and our own experience. The prescribed low natural fat diet is relaxed for patients who are asymptomatic when reaching age 5 years but medium-chain triglyceride oil is recommended before and after physical activity regardless of age. Metabolic stability, growth, development and cardiac function are satisfactory in all patients. There were no episodes of encephalopathy or hypoglycaemia but three patients had episodes of muscle pain with our without rhabdomyolysis. Body composition studies showed a negative association between dietary protein intake and percent body fat. Larger patient cohort and longer follow up time are required for further elucidation of genotype-phenotype correlations and for establishing the role of dietary protein in metabolic stability and long-term healthier body composition in patients with VLCAD deficiency.",
keywords = "Body composition, Fatty acid oxidation, VLCAD deficiency",
author = "Maureen Evans and Andresen, {Brage S.} and Judy Nation and Avihu Boneh",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.ymgme.2016.05.012",
language = "English",
volume = "118",
pages = "282--287",
journal = "Molecular Genetics and Metabolism",
issn = "1096-7192",
publisher = "Elsevier",
number = "4",

}

VLCAD deficiency : Follow-up and outcome of patients diagnosed through newborn screening in Victoria. / Evans, Maureen; Andresen, Brage S.; Nation, Judy; Boneh, Avihu.

In: Molecular Genetics and Metabolism, Vol. 118, No. 4, 01.08.2016, p. 282-287.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - VLCAD deficiency

T2 - Follow-up and outcome of patients diagnosed through newborn screening in Victoria

AU - Evans, Maureen

AU - Andresen, Brage S.

AU - Nation, Judy

AU - Boneh, Avihu

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inherited metabolic disorder of fatty acid oxidation. Treatment practices of the disorder have changed over the past 10–15 years since this disorder was included in newborn screening programs and patients were diagnosed pre-symptomatically. A genotype-phenotype correlation has been suggested but the discovery of novel mutations make this knowledge limited. Herein, we describe our experience in treating patients (n = 22) diagnosed through newborn screening and mutational confirmation and followed up over a median period of 104 months. We report five novel mutations. In 2013 we formalised our treatment protocol, which essentially follows a European consensus paper from 2009 and our own experience. The prescribed low natural fat diet is relaxed for patients who are asymptomatic when reaching age 5 years but medium-chain triglyceride oil is recommended before and after physical activity regardless of age. Metabolic stability, growth, development and cardiac function are satisfactory in all patients. There were no episodes of encephalopathy or hypoglycaemia but three patients had episodes of muscle pain with our without rhabdomyolysis. Body composition studies showed a negative association between dietary protein intake and percent body fat. Larger patient cohort and longer follow up time are required for further elucidation of genotype-phenotype correlations and for establishing the role of dietary protein in metabolic stability and long-term healthier body composition in patients with VLCAD deficiency.

AB - Very long chain acyl-CoA dehydrogenase (VLCAD) deficiency is an inherited metabolic disorder of fatty acid oxidation. Treatment practices of the disorder have changed over the past 10–15 years since this disorder was included in newborn screening programs and patients were diagnosed pre-symptomatically. A genotype-phenotype correlation has been suggested but the discovery of novel mutations make this knowledge limited. Herein, we describe our experience in treating patients (n = 22) diagnosed through newborn screening and mutational confirmation and followed up over a median period of 104 months. We report five novel mutations. In 2013 we formalised our treatment protocol, which essentially follows a European consensus paper from 2009 and our own experience. The prescribed low natural fat diet is relaxed for patients who are asymptomatic when reaching age 5 years but medium-chain triglyceride oil is recommended before and after physical activity regardless of age. Metabolic stability, growth, development and cardiac function are satisfactory in all patients. There were no episodes of encephalopathy or hypoglycaemia but three patients had episodes of muscle pain with our without rhabdomyolysis. Body composition studies showed a negative association between dietary protein intake and percent body fat. Larger patient cohort and longer follow up time are required for further elucidation of genotype-phenotype correlations and for establishing the role of dietary protein in metabolic stability and long-term healthier body composition in patients with VLCAD deficiency.

KW - Body composition

KW - Fatty acid oxidation

KW - VLCAD deficiency

UR - http://www.scopus.com/inward/record.url?scp=84969963345&partnerID=8YFLogxK

U2 - 10.1016/j.ymgme.2016.05.012

DO - 10.1016/j.ymgme.2016.05.012

M3 - Article

VL - 118

SP - 282

EP - 287

JO - Molecular Genetics and Metabolism

JF - Molecular Genetics and Metabolism

SN - 1096-7192

IS - 4

ER -